In this study published in the journal Clinical Cancer Research, the scientists developed and validated in clinical trials a multiparameter molecular classifier test to predict with a high degree of confidence which patients with HER2-positive (HER2+) breast cancer would be candidates for anti-HER2 therapy alone without the need for chemotherapy.
While environmental factors such as pesticide exposure have long been linked to Parkinson's, it has been harder to pinpoint which pesticides may raise risk for the neurodegenerative disorder.